Leishmania infantum excreted secreted proteins

This medicine is authorised for use in the European Union.


This is a summary of the European public assessment report (EPAR). Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use.

This summary cannot replace a face-to-face discussion with your veterinarian. If you need more information about your animal’s medical condition or treatment, contact your veterinarian. If you want more information on the basis of the CVMP recommendations, read the scientific discussion (also part of the EPAR).

This EPAR was last updated on 14/01/2016

Authorisation details

Product details
Agency product number
Active substance
Leishmania infantum excreted secreted proteins
International non-proprietary name (INN) or common name
Leishmania infantum excreted secreted proteins
Anatomical therapeutic chemical veterinary (ATCvet) codes
Publication details
Marketing-authorisation holder
Virbac S.A.
Date of issue of marketing authorisation valid throughout the European Union
Contact address

1ère Avenue 2065 M - L.I.D.
06516 Carros Cedex

Product information

07/01/2016 CaniLeish - EMEA/V/C/002232 - R/0004

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group


Therapeutic indication

For the active immunisation of Leishmania-negative dogs from six months of age to reduce the risk to develop an active infection and clinical disease after contact with Leishmania infantum.

The efficacy of the vaccine has been demonstrated in dogs submitted to multiple natural parasite exposure in zones with high infection pressure.

Onset of immunity: 4 weeks after the primary vaccination course.

Duration of immunity: 1 year after the last re-vaccination.

Assessment history

How useful was this page?

Add your rating
1 rating